EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs) . EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC) [1].